Apellis Pharmaceuticals Inc (FRA:1JK)
€ 36.96 -2.005 (-5.15%) Market Cap: 4.53 Bil Enterprise Value: 4.33 Bil PE Ratio: 0 PB Ratio: 18.22 GF Score: 49/100

Apellis Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 10, 2021 / 09:20PM GMT
Release Date Price: €31.8 (+11.19%)
Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

All right. Perfect. Welcome, everyone, to the 30th Annual Healthcare Conference for Crédit Suisse. I'm Tiago Fauth, here. I'm a biotech analyst here at Crédit Suisse. We're joined today by Apellis. We have Tim and we have David from the company, and we're going to have a fireside chat.

So if you guys want to try to ask in a few questions, you can send them my way, I'll try to work those in. The e-mail is Tiago -- T-I-A-G-O F-A-U-T-H @credit-suisse.com, and we can get started.

Questions & Answers

Tiago Felipe Fauth;dit Suisse AG;Timothy E. Sullivan<
CrÃ;Research Division - Research Analyst

© -

So as usual, we can start bigger picture. Updates. Huge year for you guys. I'm sure you're tired of telling the story. You just had your earnings call, but if you can give us a brief introduction, kind of the key catalysts that you had in 2021 and the outlook going forward. And then we'll take it from there.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot